title: Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.
abstract: We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Stanford University, Palo Alto.
authors.forename: Philip M
authors.initials: PM
authors.lastname: Grant
authors.affiliation: Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston.
authors.forename: Douglas
authors.initials: D
authors.lastname: Kitch
authors.affiliation: Division of Infectious Diseases, Departments of Pediatrics and Medicine, Case Western Reserve University, Cleveland.
authors.forename: Grace A
authors.initials: GA
authors.lastname: McComsey
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle.
authors.forename: Ann C
authors.initials: AC
authors.lastname: Collier
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Koletar
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora.
authors.forename: Kristine M
authors.initials: KM
authors.lastname: Erlandson
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Columbia University, New York, New York.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Yin
authors.affiliation: New England Research Institute, Watertown, Massachusetts.
authors.forename: Benedetta
authors.initials: B
authors.lastname: Bartali
authors.affiliation: Viiv Healthcare, Research Triangle, North Carolina.
authors.forename: Belinda
authors.initials: B
authors.lastname: Ha
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: Kathy
authors.initials: K
authors.lastname: Melbourne
authors.affiliation: Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
authors.forename: Todd T
authors.initials: TT
authors.lastname: Brown
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008159:Lumbar Vertebrae / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010384:Pelvic Bones / Q000473:pathology; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents
keywords: HIV infections, drug therapy/virology; anti-HIV agents, administration and dosage, adverse effects; bone density